Müller W A, Scháffer E H, Linzner U
Radiat Environ Biophys. 1980;18(1):1-11. doi: 10.1007/BF01324368.
The rare earth radionuclides 177 Lu and 153Sm were administered as single i.p. injections in NMRI mice. Lu was deposited principally (up to 60%) in the skeleton if the quantity of stable carrier was low. Increase of stable carrier enhanced deposition in the reticulo-endothelial system. Sm was preferentially deposited in the liver; the liver deposits were further increased by the addition of stable Sm. Liver doses of between 75 and 150 Gy, resulting from a single injection of 153Sm together with 2 mg/kg stable carrier, led to severe lesions in the liver five months after treatment. Administration of 177Lu resulting in skeletal doses of between 28 and 224 Gy was found to be osteosarcomogenic. Up to 40% osteosarcoma incidence was obtained in animals with 56 and 112 Gy doses in the skeleton. Skeletal doses of this order of magnitude are also known to be osteosarcomogenic when given as 90Sr injections. The analogous situation with alpha-emitters is discussed.
将稀土放射性核素177镥和153钐以单次腹腔注射的方式给予NMRI小鼠。如果稳定载体的量较低，镥主要沉积在骨骼中（高达60%）。稳定载体的增加会增强在网状内皮系统中的沉积。钐优先沉积在肝脏中；添加稳定的钐会进一步增加肝脏中的沉积量。单次注射153钐与2mg/kg稳定载体一起，导致肝脏剂量在75至150Gy之间，在治疗五个月后肝脏出现严重病变。发现给予177镥导致骨骼剂量在28至224Gy之间具有成骨肉瘤致瘤性。在骨骼剂量为56和112Gy的动物中，骨肉瘤发病率高达40%。当以90锶注射给予时，这种量级的骨骼剂量也已知具有成骨肉瘤致瘤性。文中讨论了与α发射体类似的情况。
